PT3112462T - Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano - Google Patents
Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humanoInfo
- Publication number
- PT3112462T PT3112462T PT15754783T PT15754783T PT3112462T PT 3112462 T PT3112462 T PT 3112462T PT 15754783 T PT15754783 T PT 15754783T PT 15754783 T PT15754783 T PT 15754783T PT 3112462 T PT3112462 T PT 3112462T
- Authority
- PT
- Portugal
- Prior art keywords
- human
- bispecific antibody
- antibody binding
- tlr2
- tlr4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014038438 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3112462T true PT3112462T (pt) | 2019-02-08 |
Family
ID=54009171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15754783T PT3112462T (pt) | 2014-02-28 | 2015-02-27 | Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10253105B2 (pt) |
| EP (1) | EP3112462B1 (pt) |
| JP (1) | JP6579097B2 (pt) |
| KR (1) | KR20160125965A (pt) |
| CN (1) | CN106062193B (pt) |
| BR (1) | BR112016019929A2 (pt) |
| CA (1) | CA2941014A1 (pt) |
| ES (1) | ES2709996T3 (pt) |
| MX (1) | MX2016011228A (pt) |
| PL (1) | PL3112462T3 (pt) |
| PT (1) | PT3112462T (pt) |
| RU (1) | RU2016134913A (pt) |
| TR (1) | TR201901045T4 (pt) |
| WO (1) | WO2015129858A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3048971A1 (fr) * | 2016-03-15 | 2017-09-22 | Univ Rabelais Francois | Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9927332D0 (en) | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
| JP4263953B2 (ja) | 2003-06-23 | 2009-05-13 | 三洋電機株式会社 | 半導体装置及びその製造方法 |
| JP3810388B2 (ja) | 2003-07-14 | 2006-08-16 | 株式会社中央精機 | 両頭側面フライス盤 |
| US7388080B2 (en) | 2003-08-20 | 2008-06-17 | University Of Massachusetts | Selective inhibition of toll-like receptor-2 |
| US8623353B1 (en) | 2003-09-23 | 2014-01-07 | Technische Universitat Munchen | TLR2 antagonistic antibody and use thereof |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| DK1711531T3 (da) | 2003-12-10 | 2012-04-30 | Novimmune Sa | Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf |
| MXPA06000176A (es) * | 2003-12-10 | 2006-06-27 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y sus metodos de uso. |
| DK1830881T3 (da) * | 2004-12-10 | 2010-09-20 | Novimmune Sa | Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf |
| ES2751946T3 (es) | 2009-03-20 | 2020-04-02 | Amgen Inc | Anticuerpo antagonista específico del heterodímero alfa-4-beta-7 |
| CA2757669A1 (en) * | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
| IE20090514A1 (en) * | 2009-07-06 | 2011-02-16 | Opsona Therapeutics Ltd | Humanised antibodies and uses therof |
| US9624310B2 (en) * | 2011-11-17 | 2017-04-18 | Gundram Jung | Methods of using bi-specific antibodies for treating B-cell-mediated autoimmune diseases or auto-reactive B-cells |
| EP2794658B1 (en) * | 2011-12-19 | 2017-03-15 | Synimmune GmbH | Bispecific antibody molecule |
| DK2831117T3 (en) * | 2012-03-29 | 2017-12-18 | Novimmune Sa | ANTI-TLR4 ANTIBODIES AND APPLICATIONS THEREOF |
-
2015
- 2015-02-27 KR KR1020167022970A patent/KR20160125965A/ko unknown
- 2015-02-27 CN CN201580011160.9A patent/CN106062193B/zh active Active
- 2015-02-27 CA CA2941014A patent/CA2941014A1/en not_active Abandoned
- 2015-02-27 RU RU2016134913A patent/RU2016134913A/ru not_active Application Discontinuation
- 2015-02-27 PT PT15754783T patent/PT3112462T/pt unknown
- 2015-02-27 JP JP2016505322A patent/JP6579097B2/ja active Active
- 2015-02-27 EP EP15754783.7A patent/EP3112462B1/en active Active
- 2015-02-27 WO PCT/JP2015/055860 patent/WO2015129858A1/ja active Application Filing
- 2015-02-27 BR BR112016019929A patent/BR112016019929A2/pt not_active Application Discontinuation
- 2015-02-27 TR TR2019/01045T patent/TR201901045T4/tr unknown
- 2015-02-27 ES ES15754783T patent/ES2709996T3/es active Active
- 2015-02-27 US US15/121,567 patent/US10253105B2/en active Active
- 2015-02-27 MX MX2016011228A patent/MX2016011228A/es unknown
- 2015-02-27 PL PL15754783T patent/PL3112462T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3112462A4 (en) | 2017-11-01 |
| MX2016011228A (es) | 2016-11-30 |
| US10253105B2 (en) | 2019-04-09 |
| BR112016019929A2 (pt) | 2017-10-17 |
| TR201901045T4 (tr) | 2019-02-21 |
| EP3112462A1 (en) | 2017-01-04 |
| KR20160125965A (ko) | 2016-11-01 |
| CA2941014A1 (en) | 2015-09-03 |
| JP6579097B2 (ja) | 2019-09-25 |
| RU2016134913A (ru) | 2018-03-30 |
| CN106062193A (zh) | 2016-10-26 |
| CN106062193B (zh) | 2020-08-25 |
| PL3112462T3 (pl) | 2019-06-28 |
| JPWO2015129858A1 (ja) | 2017-03-30 |
| US20160355602A1 (en) | 2016-12-08 |
| EP3112462B1 (en) | 2018-12-05 |
| WO2015129858A1 (ja) | 2015-09-03 |
| ES2709996T3 (es) | 2019-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267798B (en) | Human antibodies to pd-1 | |
| HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
| IL246661B (en) | Human antibodies to pd–l1 | |
| IL246693B2 (en) | Antibody molecules to tim-3 and their uses | |
| ZA201905341B (en) | Antibodies specifically binding to human il-1r7 | |
| PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
| PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
| SG11201705632UA (en) | Bispecific antibody binding to trailr2 and psma | |
| PT3112462T (pt) | Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano | |
| HK1245811A1 (zh) | 結合人c6的抗體及其用途 | |
| GB201408704D0 (en) | Improvement to fasteners and buckles |